Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Abstract The rapid spread of SARS-CoV-2 has a significant impact on global health, travel and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated neutralizing antibodies from convalescent COVID-19 patients using a SARS-CoV-2 stabilized prefusion spike protein. Several of these antibodies were able to potently inhibit live SARS-CoV-2 infection at concentrations as low as 0.007 µg/mL, making them the most potent human SARS-CoV-2 antibodies described to date. Mapping studies revealed that the SARS-CoV-2 spike protein contained multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as previously undefined non-RBD epitopes. In addition to providing guidance for vaccine design, these mAbs are promising candidates for treatment and prevention of COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 01. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.05.12.088716 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI017901472 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI017901472 | ||
| 003 | DE-627 | ||
| 005 | 20231205150512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200517s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.05.12.088716 |2 doi | |
| 035 | |a (DE-627)XBI017901472 | ||
| 035 | |a (biorXiv)10.1101/2020.05.12.088716 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brouwer, Philip J.M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The rapid spread of SARS-CoV-2 has a significant impact on global health, travel and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated neutralizing antibodies from convalescent COVID-19 patients using a SARS-CoV-2 stabilized prefusion spike protein. Several of these antibodies were able to potently inhibit live SARS-CoV-2 infection at concentrations as low as 0.007 µg/mL, making them the most potent human SARS-CoV-2 antibodies described to date. Mapping studies revealed that the SARS-CoV-2 spike protein contained multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as previously undefined non-RBD epitopes. In addition to providing guidance for vaccine design, these mAbs are promising candidates for treatment and prevention of COVID-19. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Caniels, Tom G. |4 aut | |
| 700 | 1 | |a van der Straten, Karlijn |4 aut | |
| 700 | 1 | |a Snitselaar, Jonne L. |4 aut | |
| 700 | 1 | |a Aldon, Yoann |4 aut | |
| 700 | 1 | |a Bangaru, Sandhya |4 aut | |
| 700 | 1 | |a Torres, Jonathan L. |4 aut | |
| 700 | 1 | |a Okba, Nisreen M.A. |4 aut | |
| 700 | 1 | |a Claireaux, Mathieu |4 aut | |
| 700 | 1 | |a Kerster, Gius |4 aut | |
| 700 | 1 | |a Bentlage, Arthur E.H. |4 aut | |
| 700 | 1 | |a van Haaren, Marlies M. |4 aut | |
| 700 | 1 | |a Guerra, Denise |4 aut | |
| 700 | 1 | |a Burger, Judith A. |4 aut | |
| 700 | 1 | |a Schermer, Edith E. |4 aut | |
| 700 | 1 | |a Verheul, Kirsten D. |4 aut | |
| 700 | 1 | |a van der Velde, Niels |4 aut | |
| 700 | 1 | |a van der Kooi, Alex |4 aut | |
| 700 | 1 | |a van Schooten, Jelle |4 aut | |
| 700 | 1 | |a van Breemen, Mariëlle J. |4 aut | |
| 700 | 1 | |a Bijl, Tom P. L. |4 aut | |
| 700 | 1 | |a Sliepen, Kwinten |4 aut | |
| 700 | 1 | |a Aartse, Aafke |4 aut | |
| 700 | 1 | |a Derking, Ronald |4 aut | |
| 700 | 1 | |a Bontjer, Ilja |4 aut | |
| 700 | 1 | |a Kootstra, Neeltje A. |4 aut | |
| 700 | 1 | |a Wiersinga, W. Joost |4 aut | |
| 700 | 1 | |a Vidarsson, Gestur |4 aut | |
| 700 | 1 | |a Haagmans, Bart L. |4 aut | |
| 700 | 1 | |a Ward, Andrew B. |4 aut | |
| 700 | 1 | |a de Bree, Godelieve J. |4 aut | |
| 700 | 1 | |a Sanders, Rogier W. |4 aut | |
| 700 | 1 | |a van Gils, Marit J. |0 (orcid)0000-0003-3422-8161 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 01. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1126/science.abc5902 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.05.12.088716 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 10 | ||